OrbiMed’s Edgewise Therapeutics EWTX Stock Holding History

OrbiMed’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$631M	Hold	15,518,492	–	–	11.68%	1
2026 Q1	$489M	Hold	15,518,492	–	–	9.69%	1
2025 Q4	$385M	Hold	15,518,492	–	–	7.86%	1
2025 Q3	$252M	Hold	15,518,492	–	–	5.92%	1
2025 Q2	$203M	Buy	15,518,492 +496,771	+3%	+$7.16M	5.08%	4
2025 Q1	$330M	Hold	15,021,721	–	–	7.88%	2
2024 Q4	$401M	Hold	15,021,721	–	–	8.25%	1
2024 Q3	$401M	Hold	15,021,721	–	–	7.29%	1
2024 Q2	$271M	Hold	15,021,721	–	–	5.34%	3
2024 Q1	$274M	Buy	15,021,721 +454,545	+3%	+$7.22M	5.02%	3
2023 Q4	$159M	Hold	14,567,176	–	–	3.18%	6
2023 Q3	$83.5M	Hold	14,567,176	–	–	1.77%	17
2023 Q2	$113M	Hold	14,567,176	–	–	2.05%	11
2023 Q1	$97.2M	Hold	14,567,176	–	–	1.91%	14
2022 Q4	$130M	Hold	14,567,176	–	–	2.49%	9
2022 Q3	$143M	Buy	14,567,176 +484,496	+3%	+$4.9M	2.66%	7
2022 Q2	$112M	Buy	14,082,680 +138,000	+1%	+$1.04M	2.03%	13
2022 Q1	$135M	Hold	13,944,680	–	–	2.19%	13
2021 Q4	$213M	Hold	13,944,680	–	–	2.74%	6
2021 Q3	$231M	Hold	13,944,680	–	–	2.54%	9
2021 Q2	$297M	Hold	13,944,680	–	–	3.01%	3
2021 Q1	$453M	Buy	+13,944,680	New	+$452M	4.24%	2

Other funds holding EWTX

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OrbiMed's EWTX Position: Q2 2026 in Review

OrbiMed held its Edgewise Therapeutics (EWTX) position steady in Q2 2026 at 15,518,492 shares worth $631M. The position accounts for 11.68% of the portfolio, ranked #1.

OrbiMed first reported a position in EWTX in Q1 2021 and has held it in 22 quarters since. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

OrbiMed held 15,518,492 shares of Edgewise Therapeutics worth $631M as of Q2 2026.
OrbiMed left its Edgewise Therapeutics share count unchanged in Q2 2026.
Edgewise Therapeutics made up 11.68% of OrbiMed's portfolio in Q2 2026, its #1 holding.
OrbiMed first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 22 quarters since.
226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.